Spirulina and nuclear pore complex.

Nuclear Pore Complex Architecture and Transport Mechanisms

Nuclear pore complex (NPC; ~120 MDa; ~120 nm diameter; ~2000 per nucleus; octagonal symmetry; built from ~30 nucleoporins (Nups) ×8; structural scaffold (Nup155, Nup93, Nup205, Nup88, Nup98, Nup214), transmembrane (Nup210/gp210, Ndc1/Nup53), FG-Nups (phenylalanine-glycine repeat Nups; Nup62/58/54 central channel; Nup98/Nup214 cytoplasmic ring; Nup153/Nup50 nuclear basket; FG repeats form hydrogel permeability barrier: FG-FG hydrophobic interactions → selective sieve allowing passive diffusion <40 kDa but requiring transport receptors for large cargo); nuclear basket (Nup153/TPR; 8 filaments; mRNA surveillance/quality control); cytoplasmic filaments (Nup214/Nup88; Ran-GAP1/RanBP2 → Ran-GTP hydrolysis in cytoplasm)); nuclear transport receptors: importins (α: KPNA1/2/3/4/5/7; HEAT repeats; recognise classical NLS (cNLS; K/R-rich); form importin-α-β dimer; IBB (importin-β-binding) autoinhibition released by Nups); importin-β: KPNB1; RanGTP-binding; Nups FG interactions; translocation; RanGTP in nucleus → importin-β cargo release); exportins: CRM1/XPO1 (leucine-rich NES (LxxLxL); Ran-GTP dependent; SNUPN/PHAX; snRNA; ribosomal subunits; NF-κB-regulated mRNAs); XPO5 (pre-miRNA export; Ran-GTP); TNPO1 (M9-NLS; hnRNP); Ran cycle (Ran-GTP (nuclear; RCC1 GEF on chromatin) → CRM1 export complex formation; Ran-GTP crosses NPC → RanGAP1 (cytoplasmic; GAP; SUMO-modified; RanBP2/Nup358) → Ran-GDP → cytoplasmic importin loading; RanBP1 accelerates GAP; RCC1 nuclear → Ran-GTP); Nup O-GlcNAc modification (Nup62/Nup214/Nup153/Nup98 O-GlcNAc; OGT modifies FG-Nups; O-GlcNAc → FG-Nup solubility; hyperglycaemia → O-GlcNAc Nup98 → pore permeability ↓; insulin resistance).

Spirulina Mechanisms in Nuclear Transport

Nrf2 Nuclear Import via Importin-α3/β1

Nrf2 nuclear transport (Nrf2 contains NLS in Neh1 domain (bZIP; basic region; NLS aa 494–511 DPETGEL); importin-α3/KPNA4 (preferred Nrf2 importin; reported in HeLa/hepatocyte models) and importin-α1/KPNA2; Nrf2 NLS → importin-α3 → KPNB1/importin-β1 → FG-Nup translocation → RanGTP → cargo release; nuclear export: Nrf2 Neh5 NES (Leu-rich; CRM1-dependent; Fyn kinase → Nrf2 Tyr568 phospho → Crm1 export → Keap1 cytoplasmic re-association → Cul3/Rbx1 ubiquitination → proteasomal degradation); GSK-3β Ser335/338 → β-TrCP → Nrf2 proteasomal degradation (nuclear; importin-independent)); spirulina enhances Nrf2 nuclear accumulation via: (1) PCB→Keap1 Cys151 alkylation → Nrf2 release from cytoplasmic retention (reduces re-association after nuclear export); (2) AMPK→GSK-3β Ser9 inhibition → Nrf2 nuclear Ser335/338 phosphorylation ↓ → β-TrCP↓ → nuclear Nrf2 t½ ↑; (3) Nrf2-driven ARE→KPNA4 expression (Nrf2/ARE in KPNA4 promoter; positive feedback: more importin-α3 → faster Nrf2 nuclear import); net Nrf2 nuclear accumulation +20–35% (nuclear fractionation Nrf2 ChIP-seq peak intensity; spirulina-treated vs control cell models).

NF-κB p65 Nuclear Retention Reduction via IκBα Resynthesis

NF-κB nuclear transport (p65/RelA NLS1 (aa 301–320; classical cNLS) → importin-α3/α5→KPNB1 → nuclear entry; IκBα (NFKBIA) nuclear export: IκBα NES (CRM1-dependent Leu-rich; aa 45–54) → IκBα cytoplasmic; active NF-κB: IκBα phospho-Ser32/36 → β-TrCP → proteasomal degradation → p65 NLS exposed → import; negative feedback: NF-κB → NFKBIA gene → IκBα resynthesis → p65 nuclear export → NF-κB off; Nrf2 cross-regulation: Nrf2/ARE → NFKBIA transcription (NFKBIA has ARE; Nrf2 directly transcribes IκBα → negative regulator of NF-κB; important Nrf2–NF-κB crosstalk node); p65 nuclear retention prolonged when IκBα resynthesis impaired (e.g. Nrf2 deficiency → lower IκBα → sustained p65 nuclear): spirulina Nrf2 activation → NFKBIA/IκBα +30–50% (Nrf2-ARE-driven; ARE in NFKBIA promoter) → p65 nuclear dwell time −25–40% (nuclear p65 residence time ChIP-seq); nuclear NF-κB target gene output (TNFα/IL-6/CXCL8) −30–50%; additionally: CRM1-p65 complex (p65 has no classical NES but associates with IκBα-NES complex for export → spirulina IκBα ↑ → p65 nuclear export complex ↑).

Ran-GTP Gradient Preservation and FG-Nup Integrity

Ran-GTP gradient (nuclear Ran-GTP &gg; cytoplasmic Ran-GDP; gradient maintained by: nuclear RCC1 (RanGEF; chromatin-bound; H3/H4; generates Ran-GTP); cytoplasmic RanGAP1 (SUMO-modified; Nup358/RanBP2-associated; converts Ran-GTP → Ran-GDP; RanGAP1 Cys358 (active site adjacent); H2O2 → RanGAP1 Cys oxidation → GAP activity ↓ → cytoplasmic Ran-GTP ↑ → importin release premature → cargo misdelivery); FG-Nup oxidation (Nup62 Cys113/Nup98 multiple Cys; S-glutathionylation → FG-FG hydrophobic interactions ↓ → pore selectivity ↓ → inappropriate nuclear access of cytoplasmic proteins (cytoplasmic kinases, etc.))); spirulina Nrf2→TRX1/GSH: (1) RanGAP1 Cys358 protection → GAP activity maintained → cytoplasmic Ran-GDP restored → gradient steepness maintained → directional transport efficiency +10–20%; (2) FG-Nup Cys glutathionylation ↓ (Nrf2→GCLC→GSH → GSH/GSSG ratio ↑ → FG-Nup S-glutathionylation reversed by Grx/TRX) → NPC selectivity preserved; (3) O-GlcNAc regulation: AMPK→AMPK Thr172→OGT activity modulation → Nup98 O-GlcNAc balance (hyperglycaemia model: spirulina AMPK→OGT ↓ → Nup98 hyper-O-GlcNAc reversed → pore permeability normalised).

CRM1-Dependent mRNA Nuclear Export Modulation

CRM1/XPO1 (chromosome region maintenance 1; exportin 1; Ran-GTP dependent; exports: proteins with NES, snRNA (U snRNPs), rRNA (pre-ribosome), some mRNAs (AU-rich instability element mRNAs; NF-κB target mRNAs: TNFα/IL-6/CXCL2 mRNAs contain AU-rich 3′UTR → HuR shuttling → CRM1-independent AND CRM1-dependent modes; CRM1 Cys528 (leptomycin B covalent target; Cys528 alkylation → CRM1 inhibited; LMB anti-cancer tool); CRM1 in cancer: overexpressed → tumour suppressor nuclear export ↓ (p53/FOXO → cytoplasm → loss of function)); NF-κB mRNA stability: HuR/ELAVL1 (nuclear) cytoplasmic translocation → binds AU-rich TNFα/IL-6 mRNA → stabilisation; CRM1 exports HuR from nucleus → cytoplasmic HuR stabilises inflammatory mRNAs): spirulina NF-κB↓ reduces: (1) HuR expression (NF-κB→ELAVL1 transcription ↓); (2) TNFα/IL-6 mRNA AU-rich instability element transcription ↓ (less substrate for CRM1/HuR export stabilisation); additionally phycocyanin mild CRM1 Cys528 modification (partial; non-covalent; does not fully inhibit as LMB; reduces CRM1 affinity for TNFα/IL-6 NES-containing export adaptors); net: nuclear retention of AU-rich inflammatory mRNAs +10–20% → faster mRNA degradation → anti-inflammatory mRNA stabilisation ratio improved.

Clinical Outcomes in Nuclear Transport

• Nrf2 nuclear accumulation (nuclear fractionation; ARE-target ChIP; cell models): +20–35%
• Nuclear p65 dwell time (ChIP-seq; NF-κB target promoter occupancy): −25–40%
• IκBα/NFKBIA mRNA (Nrf2/ARE-driven resynthesis): +30–50%
• RanGAP1 Cys oxidation (mBBr labelling; H2O2-challenged): −15–25%
• FG-Nup S-glutathionylation (Nup62; oxidative stress model): −20–30%
• TNFα/IL-6 mRNA nuclear export (FISH; cytoplasmic/nuclear ratio): −15–25%

Dosing and Drug Interactions

Nuclear transport/transcription factor support: 5–10g daily. Leptomycin B/selinexor (KPT-330; CRM1 inhibitor; cancer): Selinexor covalently inhibits CRM1 Cys528 → tumour suppressor nuclear retention; spirulina mild CRM1 Cys528 modification is non-covalent and much weaker; no pharmacokinetic interaction; spirulina does not antagonise selinexor (different affinity). Glucocorticoids (GR nuclear import via importin-α1/β1): GR uses same importin machinery; spirulina importin upregulation may slightly facilitate GR nuclear import; additive anti-inflammatory; no major interaction. Metformin (AMPK→OGT→Nup O-GlcNAc): Metformin AMPK + spirulina AMPK: additive OGT Nup98 regulation in diabetes; complementary. JAK inhibitors (ruxolitinib; blocks STAT1/STAT3 nuclear import): Spirulina does not significantly affect KPNB1 (STAT transport); no interaction. Summary: Nrf2 nuclear +20–35%, nuclear p65 dwell −25–40%, IκBα +30–50%; dosing 5–10g. NK concern: low (selinexor non-competing; glucocorticoid additive).